DNA 8-K
Ginkgo Bioworks Holdings, Inc. (DNA)
8-K
2026-04-07
For: 2026-04-03
View Original
Added on
April 09, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________
FORM 8-K
______________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 3, 2026
______________________________________________________________
(Exact name of registrant as specified in its charter)
______________________________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (877 ) 422-5362
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.01. Completion of Acquisition or Disposition of Assets.
On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”) completed the previously announced transaction (the “Transaction”) with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchaser”) pursuant to the Stock Purchase Agreement, dated as of February 26, 2026 (the “Purchase Agreement”), by and among the Seller, the Company, the Purchaser and Ginkgo Biosecurity, LLC (“Biosecurity”). On the terms and subject to the conditions in the Purchase Agreement, the Seller contributed to the Purchaser all of the issued and outstanding equity interests of Biosecurity, constituting substantially all of the Company’s operations comprising its Biosecurity segment, and in exchange, the Purchaser issued to the Seller shares of common stock of the Purchaser representing approximately 20% of the issued and outstanding equity of the Purchaser on a fully diluted basis.
The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which is filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 27, 2026.
As a result of the completion of the Transaction, the Company met the criteria set forth in Accounting Standards Codification 205-20, Presentation of Financial Statements - Discontinued Operations and is including in this Current Report on Form 8-K the unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025, and the unaudited pro forma Condensed Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023 giving effect to the Transaction as if the Transaction had occurred on January 1, 2023. The unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025 gives effect to the Transaction as if it occurred on that date.
Item 9.01. Financial Statements and Exhibits.
(b) Pro forma financial information.
The unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025, and the unaudited pro forma Condensed Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023 are filed as Exhibit 99.1 attached hereto and incorporated herein by reference.
(d)Exhibits.
| Exhibit Number | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GINKGO BIOWORKS HOLDINGS, INC. | ||||||||
| Date: April 7, 2026 | By: | /s/ Steven Coen | ||||||
| Name: | Steven Coen | |||||||
| Title: | Chief Financial Officer | |||||||
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary of Ginkgo Bioworks Holdings, Inc. (the “Company”), completed a transaction with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”) (the “Transaction”). In connection with the Transaction, Seller contributed to Purchaser all of the issued and outstanding equity interests of Biosecurity, constituting substantially all of the Company’s operations comprising its Biosecurity segment, and in exchange, the Purchaser issued to the Seller shares of common stock of the Purchaser representing approximately 20% of the issued and outstanding equity of the Purchaser on a fully diluted basis.
The Transaction represents a strategic shift and therefore, beginning with the Company’s quarterly report on Form 10-Q for the period ending March 31, 2026, the Biosecurity historical financial results for periods prior to the Transaction will be reflected in the Company’s consolidated financial statements as discontinued operations for all periods presented.
The following unaudited pro forma condensed consolidated financial statements of the Company were derived from its historical consolidated financial statements and are being presented to give effect to the Transaction. The unaudited pro forma Condensed Consolidated Statements of Operations for each of the three years ended December 31, 2025, 2024, and 2023 reflect the Company’s results as if the Transaction had occurred on January 1, 2023. The unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025 gives effect to the Transaction as if it occurred on that date.
The unaudited pro forma condensed consolidated financial statements give effect to the Transaction including: (i) the elimination of the historical Biosecurity financial results and (ii) the transfer of certain assets between the Company and the Purchaser upon closing of the Transaction.
The transaction accounting adjustments are based on available information and assumptions that the Company’s management believes are reasonable, that reflect the impact of events directly attributable to the Transaction that are factually supportable, and for purposes of the Condensed Consolidated Statements of Operations, are expected to have a continuing impact on the Company. The Company has entered into a Transition Services Agreement (“TSA”) with the Purchaser pursuant to which the Company and the Purchaser will provide each other certain specified services on a temporary basis. These transition services are not expected to have a material impact on the Company and are not recurring in nature, and as such, have not been included in the Transaction adjustments.
The unaudited pro forma condensed consolidated financial statements are subject to the assumptions and adjustments described in the accompanying notes and in the opinion of Company management, all adjustments and disclosures have been prepared in accordance with Regulation S-X, Article 11. The unaudited pro forma condensed consolidated financial statements are not intended to be a complete presentation of the Company’s financial position or results of operations had the Transaction occurred as of and for the periods indicated. In addition, the unaudited pro forma condensed consolidated financial statements are provided for illustrative and informational purposes only, and are not necessarily indicative of the Company’s historical or future results of operations or financial condition had the Transaction been completed on the dates assumed.
The unaudited pro forma condensed consolidated financial statements should be read in conjunction with (i) the audited consolidated financial statements, the accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 which are available at the Company’s website at www.ginkgobioworks.com.
Exhibit 99.1
Ginkgo Bioworks Holdings, Inc.
Unaudited Pro Forma Condensed Consolidated Balance Sheet
As of December 31, 2025
(in thousands)
| Historical | Biosecurity Separation (a) | Transaction Accounting Adjustments | Notes | Pro Forma | |||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||
| Current assets: | |||||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 167,202 | $ | — | $ | — | $ | 167,202 | |||||||||||||||||||||
| Marketable securities | 255,418 | — | — | 255,418 | |||||||||||||||||||||||||
| Accounts receivable, net | 24,255 | — | — | 24,255 | |||||||||||||||||||||||||
| Prepaid expenses and other current assets | 24,963 | — | — | 24,963 | |||||||||||||||||||||||||
| Total current assets | 471,838 | — | — | 471,838 | |||||||||||||||||||||||||
| Property, plant and equipment, net | 167,783 | (412) | — | 167,371 | |||||||||||||||||||||||||
| Operating lease right-of-use assets | 360,918 | — | — | 360,918 | |||||||||||||||||||||||||
| Investments | 15,066 | — | 12,288 | (b) | 27,354 | ||||||||||||||||||||||||
| Intangible assets, net | 56,924 | (3,442) | — | (c) | 53,482 | ||||||||||||||||||||||||
| Other non-current assets | 47,167 | — | — | 47,167 | |||||||||||||||||||||||||
| Total assets | $ | 1,119,696 | $ | (3,854) | $ | 12,288 | $ | 1,128,130 | |||||||||||||||||||||
| Liabilities and Stockholders' Equity | |||||||||||||||||||||||||||||
| Current liabilities: | |||||||||||||||||||||||||||||
| Accounts payable | $ | 10,566 | $ | — | $ | — | $ | 10,566 | |||||||||||||||||||||
| Deferred revenue | 18,946 | — | — | 18,946 | |||||||||||||||||||||||||
| Accrued expenses and other current liabilities | 66,458 | — | 1,077 | (c) | 67,535 | ||||||||||||||||||||||||
| Total current liabilities | 95,970 | — | 1,077 | 97,047 | |||||||||||||||||||||||||
| Non-current liabilities: | — | ||||||||||||||||||||||||||||
| Deferred revenue, net of current portion | 75,182 | — | — | 75,182 | |||||||||||||||||||||||||
| Operating lease liabilities, non-current | 417,078 | — | — | 417,078 | |||||||||||||||||||||||||
| Other non-current liabilities | 22,876 | — | — | 22,876 | |||||||||||||||||||||||||
| Total liabilities | 611,106 | — | 1,077 | 612,183 | |||||||||||||||||||||||||
| Stockholders' equity: | |||||||||||||||||||||||||||||
| Total stockholders' equity | 508,590 | (3,854) | 11,211 | (d) | 515,947 | ||||||||||||||||||||||||
| Total liabilities and stockholders' equity | $ | 1,119,696 | $ | (3,854) | $ | 12,288 | $ | 1,128,130 | |||||||||||||||||||||
Exhibit 99.1
Ginkgo Bioworks Holdings, Inc.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
Year Ended December 31, 2025
(in thousands, except share data)
| Historical | Biosecurity Separation (a) | Pro Forma | |||||||||||||||
| Cell Engineering revenue | $ | 132,746 | $ | — | $ | 132,746 | |||||||||||
| Biosecurity revenue: | |||||||||||||||||
| Service | 37,409 | (37,409) | — | ||||||||||||||
| Total revenue | 170,155 | (37,409) | 132,746 | ||||||||||||||
| Costs and operating expenses: | |||||||||||||||||
| Cost of Biosecurity service revenue | 31,521 | (31,521) | — | ||||||||||||||
| Cost of other revenue | 15,451 | — | 15,451 | ||||||||||||||
| Research and development | 243,773 | — | 243,773 | ||||||||||||||
| General and administrative | 183,290 | (32,972) | 150,318 | ||||||||||||||
| Restructuring charges | 11,398 | (1,922) | 9,476 | ||||||||||||||
| Total operating expenses | 485,433 | (64,262) | 419,018 | ||||||||||||||
| Loss from operations | (315,278) | 26,853 | (286,272) | ||||||||||||||
| Other income (expense): | |||||||||||||||||
| Interest income | 22,616 | (2) | 22,614 | ||||||||||||||
| Loss on investments | (16,411) | — | (16,411) | ||||||||||||||
| Other (expense) income, net | (4,527) | (1,856) | (6,383) | ||||||||||||||
| Total other income (expense) | 1,678 | (1,858) | (180) | ||||||||||||||
| Loss before income taxes | (313,600) | 24,995 | (288,605) | ||||||||||||||
| Income tax benefit | (837) | — | (837) | ||||||||||||||
| Net loss: | $ | (312,763) | $ | 24,995 | $ | (287,768) | |||||||||||
| Net loss per share | $ | (5.64) | — | $ | (6.00) | ||||||||||||
| Weighted average common shares outstanding: | 55,457,676 | — | 55,457,676 | ||||||||||||||
Exhibit 99.1
Ginkgo Bioworks Holdings, Inc.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
Year Ended December 31, 2024
(in thousands, except share data)
| Historical | Biosecurity Separation (a) | Pro Forma | |||||||||||||||
| Cell Engineering revenue | $ | 173,972 | $ | — | $ | 173,972 | |||||||||||
| Biosecurity revenue: | |||||||||||||||||
| Service | 53,071 | (53,071) | — | ||||||||||||||
| Total revenue | 227,043 | (53,071) | 173,972 | ||||||||||||||
| Costs and operating expenses: | |||||||||||||||||
| Cost of Biosecurity service revenue | 38,549 | (38,549) | — | ||||||||||||||
| Cost of other revenue | 5,999 | — | 5,999 | ||||||||||||||
| Research and development | 424,061 | (79) | 423,982 | ||||||||||||||
| General and administrative | 246,161 | (55,261) | 190,900 | ||||||||||||||
| Goodwill impairment | 47,858 | — | 47,858 | ||||||||||||||
| Restructuring charges | 24,172 | (1,236) | 22,936 | ||||||||||||||
| Total operating expenses | 786,800 | (93,595) | 691,675 | ||||||||||||||
| Loss from operations | (559,757) | 40,524 | (517,703) | ||||||||||||||
| Other income (expense): | |||||||||||||||||
| Interest income | 38,612 | — | 38,612 | ||||||||||||||
| Interest expense | (94) | — | (94) | ||||||||||||||
| Loss on investments | (28,827) | — | (28,827) | ||||||||||||||
| Loss on deconsolidation of subsidiaries | (7,013) | — | (7,013) | ||||||||||||||
| Change in fair value of warrant liabilities | 5,701 | — | 5,701 | ||||||||||||||
| Other income (expense), net | 3,870 | (1,105) | 2,765 | ||||||||||||||
| Total other income (expense) | 12,249 | (1,105) | 11,144 | ||||||||||||||
| Loss before income taxes | (547,508) | 39,419 | (508,089) | ||||||||||||||
| Income tax benefit | (479) | — | (479) | ||||||||||||||
| Net loss: | $ | (547,029) | $ | 39,419 | $ | (507,610) | |||||||||||
| Net loss per share | $ | (10.54) | $ | — | $ | (11.00) | |||||||||||
| Weighted average common shares outstanding: | 51,894,639 | — | 51,894,639 | ||||||||||||||
Exhibit 99.1
Ginkgo Bioworks Holdings, Inc.
Unaudited Pro Forma Condensed Consolidated Statement of Operations
Year Ended December 31, 2023
(in thousands, except share data)
| Historical | Biosecurity Separation (a) | Pro Forma | |||||||||||||||
| Cell Engineering revenue | $ | 143,531 | $ | — | $ | 143,531 | |||||||||||
| Biosecurity revenue: | |||||||||||||||||
| Service | 78,975 | (78,975) | — | ||||||||||||||
| Product | 28,949 | (28,949) | — | ||||||||||||||
| Total revenue | 251,455 | (107,924) | 143,531 | ||||||||||||||
| Costs and operating expenses: | |||||||||||||||||
| Cost of Biosecurity service revenue | 46,524 | (46,524) | — | ||||||||||||||
| Cost of Biosecurity product revenue | 7,481 | (7,481) | — | ||||||||||||||
| Research and development | 580,621 | (173) | 580,448 | ||||||||||||||
| General and administrative | 385,025 | (73,155) | 311,870 | ||||||||||||||
| Impairment of lease assets | 96,210 | — | 96,210 | ||||||||||||||
| Total operating expenses | 1,115,861 | (126,960) | 988,528 | ||||||||||||||
| Loss from operations | (864,406) | 19,036 | (844,997) | ||||||||||||||
| Other income (expense): | |||||||||||||||||
| Interest income | 57,217 | (7) | 57,210 | ||||||||||||||
| Interest expense | (93) | — | (93) | ||||||||||||||
| Loss on equity method investments | (2,635) | — | (2,635) | ||||||||||||||
| Loss on investments | (54,827) | — | (54,827) | ||||||||||||||
| Loss on deconsolidation of subsidiaries | (42,502) | — | (42,502) | ||||||||||||||
| Change in fair value of warrant liabilities | 5,168 | — | 5,168 | ||||||||||||||
| Other income (expense), net | 9,138 | (982) | 8,156 | ||||||||||||||
| Total other income (expense) | (28,534) | (989) | (29,523) | ||||||||||||||
| Loss before income taxes | (892,940) | 18,047 | (874,893) | ||||||||||||||
| Income tax benefit | (71) | — | (71) | ||||||||||||||
| Net loss: | $ | (892,869) | $ | 18,047 | $ | (874,822) | |||||||||||
| Net loss per share | $ | (18.37) | $ | — | $ | (18.00) | |||||||||||
| Weighted average common shares outstanding: | 48,610,507 | — | 48,610,507 | ||||||||||||||
Exhibit 99.1
GINKGO BIOWORKS HOLDINGS, INC.
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025, and the unaudited pro forma Condensed Consolidated Statements of Operations for the years ended December 31, 2025, 2024, and 2023 include the following pro forma adjustments:
a.Represents the operations, assets, liabilities and equity of Biosecurity, which have been derived from the historical consolidated financial statements. The amounts are considered preliminary, and as such, actual results could materially differ from these estimates.
b.Represents the Company’s equity interest in the Purchaser, which will be accounted for under the equity method of accounting. The valuation is considered preliminary, and as such, the final valuation could materially differ from this estimate.
c.Reflects the transfer of certain assets or liabilities assumed between the Company and the Purchaser upon closing of the Transaction.
d. Reflects the effect on total stockholders’ equity of the Transaction accounting adjustments described in footnote (b) and (c) above.